IntraBiotics reports slow enrollment in Phase III

IBPI said the rate of patient enrollment in its U.S. Phase III trial of Ramoplanin, an oral inhibitor of gram-positive bacterial cell wall synthesis to treat vancomycin-resistant enterococci (VRE) blo...